Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2020

Summary of Significant Accounting Policies

Schedule of reconciliation of the cash, cash equivalents and restricted cash amounts

	December 31, 2020		December 31, 2019
Cash and cash equivalents	$	34,224	$	119,176
Restricted cash, included in other assets		5,000		—
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	39,224	$	119,176

Schedule of the Company's net sales by medical indication

	Three Months Ended				Six Months Ended
(In thousands)	December 31,				December 31,
Medical Indication	2020		2019		2020		2019
Analgesic	$	3,572	$	2,111	$	6,692	$	3,995
Anti-Psychosis		13,317		22,697		26,345		50,730
Cardiovascular		16,336		23,972		36,050		45,579
Central Nervous System		24,614		19,331		47,139		38,588
Endocrinology		9,496		—		12,729		—
Gastrointestinal		18,575		18,313		35,675		35,275
Infectious Disease		23,044		18,078		44,976		29,973
Migraine		6,083		10,878		15,773		20,021
Respiratory/Allergy/Cough/Cold		2,267		3,075		3,693		5,781
Urinary		1,361		1,233		2,819		1,668
Other		8,410		9,934		16,044		19,796
Contract manufacturing revenue		6,845		6,488		12,464		12,046
Total net sales	$	133,920	$	136,110	$	260,399	$	263,452

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2020		2019		2020		2019
Product 1	15	%	10	%	15	%	9	%
Product 2	8	%	15	%	8	%	18	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2020		2019		2020		2019
Customer A	26	%	21	%	26	%	23	%
Customer B	21	%	26	%	22	%	26	%
Customer C	12	%	8	%	11	%	10	%